Vaccinex, Inc.
VCNXNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for VCNX. That does not mean none is planned.
Get an email about VCNX's next catalysts
Track Vaccinex (VCNX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula polymorpha)
Norovirus Infections
2 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)
Human Papillomavirus (HPV) Infection
11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
HPV InfectioN
VX15/2503
Huntington's Disease
Pepinemab
Alzheimer Disease
Avelumab and Pepinemab
Metastatic Pancreatic Adenocarcinoma
SARS-CoV-2 (LVRNA009) group
SARS-CoV-2
low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
COVID-19
VX15/2503 + avelumab
Carcinoma, Non-Small-Cell Lung
pepinemab + pembrolizumab
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula polymorpha) | Phase 3 | Norovirus Infections | - | - |
2 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) | Phase 3 | Human Papillomavirus (HPV) Infection | - | - |
11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha) | Phase 3 | HPV InfectioN | - | - |
VX15/2503 | Phase 2 | Huntington's Disease | - | - |
Pepinemab | Phase 2 | Alzheimer Disease | - | - |
Avelumab and Pepinemab | Phase 2 | Metastatic Pancreatic Adenocarcinoma | - | - |
SARS-CoV-2 (LVRNA009) group | Phase 2 | SARS-CoV-2 | - | - |
low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) | Phase 2 | COVID-19 | - | - |
VX15/2503 + avelumab | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
pepinemab + pembrolizumab | Phase 2 | Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) | - | - |
Frequently asked questions
What is in Vaccinex, Inc.'s drug pipeline?→
CatalystAlert tracks 10 drug candidates in Vaccinex, Inc.'s (VCNX) pipeline across Phase 3, Phase 2. Its lead program is 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Vaccinex, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Vaccinex, Inc. (VCNX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track VCNX biotech catalysts?→
Add VCNX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Vaccinex, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
